Skip Navigation

Journal of Antimicrobial Chemotherapy 2009 64(Supplement 1):i19-i23; doi:10.1093/jac/dkp257
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Reynolds, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

This article appears in the following Journal of Antimicrobial Chemotherapy issue: Aspects of Antimicrobial Resistance [View the issue table of contents]

Articles

Antimicrobial resistance in the UK and Ireland

Rosy Reynolds*

Department of Medical Microbiology, Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK


* Tel: +44-117-959-4080; Fax: +44-117-959-3154; E-mail: rreynolds{at}bsac.org.uk

After the dramatic expansion of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella in the UK and Ireland from 2001 onwards, the situation appears to have stabilized, with similar ESBL prevalence detected in 2007 as in 2006. Equally dramatic, but more welcome, is the sharp reduction since 2005 in the number of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemias in England, and the reduction in prevalence of MRSA as a proportion of all S. aureus bacteraemias. These two trends dominate the information from the major resistance surveillance schemes in the UK and Ireland, but a wealth of further detail is available from these rich information sources.

Resistance rates vary between hospitals, between specialities within hospitals and between patients within specialities depending on their characteristics such as age. In addition, resistance varies over time as new genetic mechanisms appear in clinically relevant bacteria, and spread or retreat under the pressures of competition and changing patterns of antibiotic use. Up-to-date information is required, not only at a national level for research and policy purposes, but at a very local level to inform day-to-day clinical decisions.

Keywords: surveillance , bacteraemia , respiratory infection , MRSA , ESBL


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.